We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.51 | -0.40% | 127.00 | 127.73 | 126.76 | 127.32 | 6,551,963 | 01:00:00 |
From May 2021 to May 2024
By Chris Wack
Ligand Pharmaceuticals Inc. shares were up 7% at $120.70 after the company said its partner, Merck, has received approval from the U.S. Food and Drug Administration for Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae in adults 18 years of age and older.
The company said Vaxneuvance is a 15-valent pneumococcal vaccine using its CRM197 vaccine carrier protein, which is produced using the patent-protected Pelican Expression Technology platform.
Under the terms of its licensing agreement with Merck, Ligand earned a $2 million milestone payment upon the FDA's approval of Vaxneuvance and is entitled to a low-single-digit royalty on net product sales.
Merck plans to submit a supplemental regulatory licensure application with the FDA later this year for the use of Vaxneuvance in children.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
July 19, 2021 13:49 ET (17:49 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
